title: Innovations in conservative endometriosis treatment: an updated review.
abstract: Endometriosis is a common, benign and chronic gynecological disorder. It is also an estrogen-dependent disorder that can result in intractable dysmenorrhea, heavy and/or irregular periods, painful bowel movements and urination during menstruation and infertility and ultimatively in repeated surgeries. Although surgery to remove endometriotic lesions is effective in relieving endometriosis-associated pain, recurrence rates are high and many women require continuous medical therapy to control symptoms. Symptom relief with palliation of pain and optimization of the quality of life should be the main aim of the medical therapy. Different pharmacologic treatment options are currently available. The most widely exerted medical therapy for endometriosis involves gonadotropin-releasing hormone (GnRH) agonists and oral contraceptives. Also progestogens and androgen derivates are used. New treatment options that are currently under investigation are selective progestogen receptor modulators (SPRMs), aromatase inhibitors (AI), GnRH- antagonists, cyclooxygenase (COX)-2 inhibitors, angiogenesis disruptor's und immune modulators. Although these new agents are promising, further confirmation in randomized clinical trials is required.
authors.affiliation: University of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Ruhland
authors.forename: A
authors.initials: A
authors.lastname: Agic
authors.forename: J
authors.initials: J
authors.lastname: Krampe
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
authors.forename: D
authors.initials: D
authors.lastname: Hornung
mesh_terms: D004715:Endometriosis / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005544:Forecasting; D006728:Hormones / Q000627:therapeutic use; D006801:Humans
chemical_list: D006728:Hormones